Baseline characteristics of patients included in the analyses by donor type (% calculations accounting for missing data)
| Characteristics . | MSD (n = 298) . | Haplo (n = 119) . | MUD (n = 551) . | MMUD (n = 64) . | P value . |
|---|---|---|---|---|---|
| Patient related | |||||
| Median age at HCT (range), y | 61.4 (21.5-72.6) | 62.5 (34.4-74.8) | 63 (32.1-77.9) | 59.3 (38.3-72.3) | <.01∗ |
| Age at HCT | <.01† | ||||
| ≤60 y | 139 (47) | 49 (41) | 217 (39) | 38 (59) | |
| >60 y | 159 (53) | 70 (59) | 334 (61) | 26 (41) | |
| Male sex | 180 (60) | 71 (60) | 316 (57) | 37 (58) | .85† |
| Race/ethnicity | <.01† | ||||
| White, not Hispanic | 239 (80) | 70 (59) | 494 (90) | 49 (77) | |
| African American, not Hispanic | 16 (5) | 19 (16) | 12 (2) | 8 (13) | |
| Asian, not Hispanic | 16 (5) | 8 (7) | 10 (2) | 1 (2) | |
| Hispanic | 20 (7) | 17 (14) | 20 (4) | 5 (8) | |
| Other | 4 (1) | 1 (1) | 8 (2) | 0 | |
| KPS at HCT | .24† | ||||
| 90-100 | 165 (55) | 58 (49) | 277 (50) | 31 (48) | |
| <90 | 128 (43) | 61 (51) | 269 (49) | 31 (48) | |
| HCT-CI at HCT | .59† | ||||
| 0-2 | 151 (51) | 60 (50) | 274 (50) | 31 (48) | |
| ≥3 | 145 (49) | 59 (50) | 266 (48) | 32 (50) | |
| Disease related | |||||
| Primary myelofibrosis | 210 (71) | 85 (71) | 395 (72) | 49 (77) | .86† |
| Post-ET/PV myelofibrosis | 85 (29) | 33 (28) | 145 (26) | 15 (23) | |
| Median time from diagnosis to HCT (range), mo | 25.3 (1.9-416.5) | 32.8 (2.4-400.5) | 28.3 (2.5-521.8) | 28.2 (4.2-363.4) | .53∗ |
| Prior use of JAK inhibitors | 188 (63) | 77 (65) | 371 (67) | 39 (61) | .34† |
| DIPSS at HCT | <.01† | ||||
| Low | 39 (13) | 14 (12) | 46 (8) | 14 (22) | |
| Intermediate-1 | 104 (35) | 33 (28) | 197 (36) | 17 (27) | |
| Intermediate-2 | 97 (33) | 45 (38) | 234 (43) | 26 (41) | |
| High | 6 (2) | 4 (3) | 8 (2) | 0 | |
| Cytogenetics | .87† | ||||
| Favorable | 148 (50) | 64 (54) | 276 (50) | 32 (50) | |
| Unfavorable/very high risk | 147 (49) | 54 (45) | 264 (48) | 29 (45) | |
| Spleen status at HCT | .18† | ||||
| No splenomegaly | 91 (31) | 52 (44) | 212 (39) | 22 (34) | |
| Splenomegaly | 151 (51) | 53 (45) | 257 (47) | 35 (55) | |
| Splenectomy | 11 (4) | 2 (2) | 23 (4) | 2 (3) | |
| Splenic radiation before HCT | 9 (3) | 1 (1) | 28 (5) | 2 (3) | N/a |
| Blasts in the bone marrow at HCT | .33† | ||||
| <5% | 220 (74) | 86 (74) | 406 (72) | 46 (72) | |
| 5%-9.99% | 26 (9) | 18 (15) | 48 (9) | 6 (9) | |
| HCT related | |||||
| Donor age, y | <.01† | ||||
| 0-17 | 1 (<1) | 4 (3) | 0 | 0 | |
| 18-29 | 1 (<1) | 40 (34) | 340 (62) | 34 (53) | |
| 30-39 | 3 (1) | 40 (34) | 132 (24) | 16 (25) | |
| 40-49 | 36 (12) | 28 (24) | 57 (10) | 6 (9) | |
| 50-59 | 126 (42) | 6 (5) | 18 (3) | 7 (11) | |
| 60-69 | 117 (39) | 1 (1) | 1 (<1) | 0 | |
| 70-79 | 14 (5) | 0 | 0 | 0 | |
| Conditioning intensity | <.01† | ||||
| Myeloablative | 142 (48) | 31 (26) | 243 (44) | 30 (47) | |
| Reduced intensity | 142 (48) | 44 (37) | 296 (54) | 31 (49) | |
| Nonmyeloablative | 11 (4) | 43 (36) | 9 (2) | 2 (3) | |
| GVHD prophylaxis | <.01† | ||||
| PTCy based | 28 (9) | 119 (100) | 58 (11) | 11 (17) | |
| CNI MMF | 35 (12) | 0 | 72 (13) | 8 (13) | |
| CNI MTX | 205 (69) | 0 | 357 (65) | 40 (63) | |
| CNI ± others | 29 (10) | 0 | 57 (10) | 5 (8) | |
| Others | 1 (<1) | 0 | 7 (1) | 0 | |
| ATG/Campath | 31 (10) | 2 (2) | 174 (32) | 30 (47) | <.01† |
| Median CD34+ cell dose (range), ×106/kg | 6.1 (0.1-32.3) | 5.5 (0.1-26.5) | 6.7 (0-73.6) | 6.3 (1.5-29.5) | .12∗ |
| CD34+ cell dose <2 × 106/kg | 9 (3) | 6 (5) | 13 (2) | 2 (3) | .86† |
| CD34+ cell dose <4 × 106/kg | 25 (8) | 10 (8) | 43 (8) | 6 (9) | |
| Donor/recipient sex match | <.01† | ||||
| M/M | 101 (34) | 45 (38) | 234 (43) | 20 (31) | |
| M/F | 55 (19) | 23 (19) | 166 (30) | 12 (19) | |
| F/M | 79 (27) | 26 (22) | 82 (15) | 16 (25) | |
| F/F | 63 (21) | 25 (21) | 68 (12) | 15 (23) | |
| Donor/recipient CMV serostatus | <.01† | ||||
| +/+ | 110 (37) | 40 (34) | 137 (25) | 17 (27) | |
| +/− | 51 (17) | 10 (8) | 86 (16) | 11 (17) | |
| −/+ | 57 (19) | 34 (29) | 129 (23) | 23 (36) | |
| −/− | 78 (26) | 34 (29) | 197 (36) | 13 (20) | |
| Year of HCT | <.01† | ||||
| 2013 | 8 (3) | 1 (1) | 18 (3) | 6 (9) | |
| 2014 | 24 (8) | 4 (3) | 59 (11) | 9 (14) | |
| 2015 | 23 (11) | 3 (3) | 48 (9) | 6 (9) | |
| 2016 | 29 (10) | 7 (6) | 58 (11) | 10 (16) | |
| 2017 | 65 (22) | 20 (17) | 118 (21) | 8 (13) | |
| 2018 | 68 (23) | 32 (27) | 141 (26) | 8 (13) | |
| 2019 | 71 (24) | 52 (44) | 109 (20) | 17 (27) | |
| Median follow-up | 46 (13-100) | 36 (9-77) | 48 (4-98) | 49 (23-98) | |
| Characteristics . | MSD (n = 298) . | Haplo (n = 119) . | MUD (n = 551) . | MMUD (n = 64) . | P value . |
|---|---|---|---|---|---|
| Patient related | |||||
| Median age at HCT (range), y | 61.4 (21.5-72.6) | 62.5 (34.4-74.8) | 63 (32.1-77.9) | 59.3 (38.3-72.3) | <.01∗ |
| Age at HCT | <.01† | ||||
| ≤60 y | 139 (47) | 49 (41) | 217 (39) | 38 (59) | |
| >60 y | 159 (53) | 70 (59) | 334 (61) | 26 (41) | |
| Male sex | 180 (60) | 71 (60) | 316 (57) | 37 (58) | .85† |
| Race/ethnicity | <.01† | ||||
| White, not Hispanic | 239 (80) | 70 (59) | 494 (90) | 49 (77) | |
| African American, not Hispanic | 16 (5) | 19 (16) | 12 (2) | 8 (13) | |
| Asian, not Hispanic | 16 (5) | 8 (7) | 10 (2) | 1 (2) | |
| Hispanic | 20 (7) | 17 (14) | 20 (4) | 5 (8) | |
| Other | 4 (1) | 1 (1) | 8 (2) | 0 | |
| KPS at HCT | .24† | ||||
| 90-100 | 165 (55) | 58 (49) | 277 (50) | 31 (48) | |
| <90 | 128 (43) | 61 (51) | 269 (49) | 31 (48) | |
| HCT-CI at HCT | .59† | ||||
| 0-2 | 151 (51) | 60 (50) | 274 (50) | 31 (48) | |
| ≥3 | 145 (49) | 59 (50) | 266 (48) | 32 (50) | |
| Disease related | |||||
| Primary myelofibrosis | 210 (71) | 85 (71) | 395 (72) | 49 (77) | .86† |
| Post-ET/PV myelofibrosis | 85 (29) | 33 (28) | 145 (26) | 15 (23) | |
| Median time from diagnosis to HCT (range), mo | 25.3 (1.9-416.5) | 32.8 (2.4-400.5) | 28.3 (2.5-521.8) | 28.2 (4.2-363.4) | .53∗ |
| Prior use of JAK inhibitors | 188 (63) | 77 (65) | 371 (67) | 39 (61) | .34† |
| DIPSS at HCT | <.01† | ||||
| Low | 39 (13) | 14 (12) | 46 (8) | 14 (22) | |
| Intermediate-1 | 104 (35) | 33 (28) | 197 (36) | 17 (27) | |
| Intermediate-2 | 97 (33) | 45 (38) | 234 (43) | 26 (41) | |
| High | 6 (2) | 4 (3) | 8 (2) | 0 | |
| Cytogenetics | .87† | ||||
| Favorable | 148 (50) | 64 (54) | 276 (50) | 32 (50) | |
| Unfavorable/very high risk | 147 (49) | 54 (45) | 264 (48) | 29 (45) | |
| Spleen status at HCT | .18† | ||||
| No splenomegaly | 91 (31) | 52 (44) | 212 (39) | 22 (34) | |
| Splenomegaly | 151 (51) | 53 (45) | 257 (47) | 35 (55) | |
| Splenectomy | 11 (4) | 2 (2) | 23 (4) | 2 (3) | |
| Splenic radiation before HCT | 9 (3) | 1 (1) | 28 (5) | 2 (3) | N/a |
| Blasts in the bone marrow at HCT | .33† | ||||
| <5% | 220 (74) | 86 (74) | 406 (72) | 46 (72) | |
| 5%-9.99% | 26 (9) | 18 (15) | 48 (9) | 6 (9) | |
| HCT related | |||||
| Donor age, y | <.01† | ||||
| 0-17 | 1 (<1) | 4 (3) | 0 | 0 | |
| 18-29 | 1 (<1) | 40 (34) | 340 (62) | 34 (53) | |
| 30-39 | 3 (1) | 40 (34) | 132 (24) | 16 (25) | |
| 40-49 | 36 (12) | 28 (24) | 57 (10) | 6 (9) | |
| 50-59 | 126 (42) | 6 (5) | 18 (3) | 7 (11) | |
| 60-69 | 117 (39) | 1 (1) | 1 (<1) | 0 | |
| 70-79 | 14 (5) | 0 | 0 | 0 | |
| Conditioning intensity | <.01† | ||||
| Myeloablative | 142 (48) | 31 (26) | 243 (44) | 30 (47) | |
| Reduced intensity | 142 (48) | 44 (37) | 296 (54) | 31 (49) | |
| Nonmyeloablative | 11 (4) | 43 (36) | 9 (2) | 2 (3) | |
| GVHD prophylaxis | <.01† | ||||
| PTCy based | 28 (9) | 119 (100) | 58 (11) | 11 (17) | |
| CNI MMF | 35 (12) | 0 | 72 (13) | 8 (13) | |
| CNI MTX | 205 (69) | 0 | 357 (65) | 40 (63) | |
| CNI ± others | 29 (10) | 0 | 57 (10) | 5 (8) | |
| Others | 1 (<1) | 0 | 7 (1) | 0 | |
| ATG/Campath | 31 (10) | 2 (2) | 174 (32) | 30 (47) | <.01† |
| Median CD34+ cell dose (range), ×106/kg | 6.1 (0.1-32.3) | 5.5 (0.1-26.5) | 6.7 (0-73.6) | 6.3 (1.5-29.5) | .12∗ |
| CD34+ cell dose <2 × 106/kg | 9 (3) | 6 (5) | 13 (2) | 2 (3) | .86† |
| CD34+ cell dose <4 × 106/kg | 25 (8) | 10 (8) | 43 (8) | 6 (9) | |
| Donor/recipient sex match | <.01† | ||||
| M/M | 101 (34) | 45 (38) | 234 (43) | 20 (31) | |
| M/F | 55 (19) | 23 (19) | 166 (30) | 12 (19) | |
| F/M | 79 (27) | 26 (22) | 82 (15) | 16 (25) | |
| F/F | 63 (21) | 25 (21) | 68 (12) | 15 (23) | |
| Donor/recipient CMV serostatus | <.01† | ||||
| +/+ | 110 (37) | 40 (34) | 137 (25) | 17 (27) | |
| +/− | 51 (17) | 10 (8) | 86 (16) | 11 (17) | |
| −/+ | 57 (19) | 34 (29) | 129 (23) | 23 (36) | |
| −/− | 78 (26) | 34 (29) | 197 (36) | 13 (20) | |
| Year of HCT | <.01† | ||||
| 2013 | 8 (3) | 1 (1) | 18 (3) | 6 (9) | |
| 2014 | 24 (8) | 4 (3) | 59 (11) | 9 (14) | |
| 2015 | 23 (11) | 3 (3) | 48 (9) | 6 (9) | |
| 2016 | 29 (10) | 7 (6) | 58 (11) | 10 (16) | |
| 2017 | 65 (22) | 20 (17) | 118 (21) | 8 (13) | |
| 2018 | 68 (23) | 32 (27) | 141 (26) | 8 (13) | |
| 2019 | 71 (24) | 52 (44) | 109 (20) | 17 (27) | |
| Median follow-up | 46 (13-100) | 36 (9-77) | 48 (4-98) | 49 (23-98) | |
ATG, antithymocyte globulin; CMV, cytomegalovirus; CNI, calcineurin inhibitors; ET, essential thrombocythemia; F, female; HCT-CI, hematopoietic cell transplantation-specific comorbidity index; KPS, Karnofsky performance status; M, male; MMF, mycophenolate mofetil; MTX, methotrexate; N/a, not available (due to low numbers); PV, polycythemia vera.
Kruskal-Wallis test was used for hypothesis testing.
Fisher exact test was used for hypothesis testing. Differences highlighted in bold.